# Supernus posts Q3 growth as Indivior merger nears its November 2 close

> Supernus reported record third-quarter revenue and raised standalone guidance, while Indivior delivered record SUBLOCADE sales and EBITDA before the companies are expected to combine on November 2.

Source page: https://stoqly.net/news/supernus-q3-2026-indivior-merger

- **Published:** 2026-11-01T03:38:26+00:00
- **Section:** Quarterly results
- **Company:** Supernus Pharmaceuticals, Inc. (SUPN), https://stoqly.net/companies/supn.md

Supernus Pharmaceuticals reported record third-quarter 2026 revenue of **$226.8 million**, up **18%** from $192.1 million a year earlier. The result was above published revenue estimates ranging from roughly $217.6 million to $223.7 million, although diluted GAAP EPS of **$0.35** was below one published $0.56 consensus estimate.

## Growth products drove the quarter

Revenue from the four growth products—Qelbree, GOCOVRI, ZURZUVAE and ONAPGO—reached **$192.2 million**, up 29% year over year. Qelbree sales rose 12% to $90.8 million, collaboration revenue from ZURZUVAE more than doubled to $41.7 million, and ONAPGO sales reached $17.1 million versus $6.8 million a year earlier. GOCOVRI sales rose 4% to a record $42.6 million.

Supernus swung to **$20.9 million of net income**, or $0.35 per diluted share, from a $45.1 million loss, or $0.80 loss per share, in the prior-year quarter. Operating earnings were $21.2 million versus a $60.2 million operating loss, helped by higher revenue and the absence of acquisition-related costs tied to the 2025 Sage acquisition. Adjusted operating earnings increased to $55.2 million from $41.9 million.

## Higher standalone guidance has a short shelf life

The company raised its standalone 2026 revenue outlook to **$875 million–$900 million**, from $860 million–$890 million, and lifted adjusted operating-earnings guidance to $160 million–$180 million from $150 million–$180 million. It also raised its ONAPGO sales outlook to $60 million–$65 million. Supernus said these forecasts cease to apply if the merger with Indivior closes as expected on November 2.

Cash, cash equivalents and current marketable securities were about **$359.5 million** at September 30, up from $308.7 million at December 31, 2025, with the company attributing the increase primarily to cash generated from operations. ONAPGO prescriptions grew 17% from the second quarter, and the company said it submitted an application for a second supplier that could receive FDA approval by mid-2027.

## Indivior adds scale before the combination

Indivior separately reported third-quarter revenue of **$356 million**, up 13% year over year, while SUBLOCADE revenue rose 22% to a record $267 million. GAAP net income reached $137 million from $42 million, adjusted EBITDA rose 76% to $211 million, and cash and investments ended the quarter at $332 million. Indivior said it remained on track for its previously communicated standalone 2026 guidance, which also stops applying at closing.

Shareholders of both companies approved the all-stock transaction on October 15. The expected combined company will be named Supernus, Inc., is expected to realize **$125 million in annual cost synergies**, and is scheduled to begin trading under the **SUPN** ticker on November 3. The filings describe the closing as expected, not completed; a closing announcement remains the next material confirmation point.

**What matters next** The earnings releases show stronger operating momentum at both companies, but the key near-term event is execution of the expected November 2 closing and the combined company’s first post-merger outlook. Standalone guidance should not be carried into the combined entity without a new disclosure.

- Supernus Q3 revenue: $226.8M +18% YoY reported
- Supernus FY26 revenue guide: $875–900M raised standalone
- Indivior Q3 SUBLOCADE: $267M +22% YoY record
- Expected annual synergies: $125M merger plan before closing

- [Supernus Q3 2026 financial results and merger update, SEC Exhibit 99.1, filed 29 October 2026](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000050/ex991earningsrelease.htm)
- [Indivior Q3 2026 financial results and merger update, SEC Form 8-K Exhibit 99.1, filed 29 October 2026](https://www.sec.gov/Archives/edgar/data/1625297/000119312526436954/d169609d425.htm)
- [Supernus investor-relations Q3 2026 results release, 29 October 2026](https://ir.supernus.com/news-releases/news-release-details/supernus-announces-third-quarter-2026-financial-results)
- [Published Q3 2026 earnings-consensus comparison for Supernus](https://ca.investing.com/news/stock-market-news/earnings-call-transcript-supernus-beats-revenue-in-q3-2026-misses-eps-93CH-4915639)

---

Written by Stoqly from SEC filings and market data. For information only — not investment advice or a recommendation to buy, sell or hold any security.